



The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Original article

Assessment of health-related quality of life and related factors in patients with chronic liver disease



Neila Paula de Souza^{a,*}, Livia Melo Villar^b, Artênio José Ísper Garbin^a,
Tânia Adas Saliba Rovida^a, Cléa Adas Saliba Garbin^a

^a Preventive and Social Dentistry Post-graduation Program, Universidade Estadual Paulista “Júlio de Mesquita Filho” (UNESP), Araçatuba, SP, Brazil

^b Laboratório de Hepatites Virais, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil

ARTICLE INFO

Article history:

Received 1 April 2015

Accepted 5 August 2015

Available online 9 September 2015

Keywords:

Quality of life

Hepatitis

Liver cirrhosis

ABSTRACT

Background and objectives: Assessing health-related quality of life is an important aspect of clinical practice. Thus, the present study attempts to assess the health-related quality of life of patients with chronic liver disease.

Methods: A cross-sectional survey was conducted on 133 chronic liver disease patients, using three instruments: a demographic questionnaire, the Chronic Liver Disease Questionnaire, and Model for End-Stage Liver Disease index. Variables were expressed as frequencies, percentages, means, and standard deviations. The statistical analysis included Pearson's correlation, Student's t-test, and analysis of variance ($p < 0.05$ was considered significant).

Results: The mean age of included subjects was 50.5 ± 13.3 years. The majority were male (66.2%), Caucasian (70.7%), and had a family income of US\$329–US\$658.2. Over half of the patients (56.4%) were infected by hepatitis C virus and 93.2% had low Model for End-Stage Liver Disease scores. Model for End-Stage Liver Disease score was related to age ($r = 0.185$; $p = 0.033$). Higher mean Chronic Liver Disease Questionnaire scores were obtained for emotional function ($39.70/\text{SD} \pm 12.98$) and while lower scores were obtained for abdominal symptoms ($16.00/\text{SD} \pm 6.25$). Fifty-two patients (39.1%) presented overall low (<5) Chronic Liver Disease Questionnaire scores. Furthermore, Chronic Liver Disease Questionnaire score was related to family income ($r = 0.187$, $p = 0.031$).

Conclusion: Most individuals presented high mean Chronic Liver Disease Questionnaire scores, indicating low health-related quality of life, especially individuals with low family income.

© 2015 Elsevier Editora Ltda. All rights reserved.

Introduction

Chronic diseases in general are increasingly widespread,¹ and diseases of the liver in particular are considered a

global public health problem.² Chronic liver disease (CLD) substantially contributes to mortality and morbidity rates.^{3,4} Worldwide, about 500 million individuals have CLD with a viral etiology.⁵ However, CLD also has non-viral etiology including alcoholic hepatitis, fatty liver, autoimmune

* Corresponding author at: Programme in Preventive and Social Dentistry, Araçatuba Dental School, Estadual Paulista University – UNESP, 1193 José Bonifácio Street, Vila Mendonça, Zip code: 16015-050, Araçatuba, São Paulo, Brazil.

E-mail address: neilapsouza@hotmail.com (N.P.d. Souza).

<http://dx.doi.org/10.1016/j.bjid.2015.08.003>

1413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.

hepatitis, cryptogenic hepatitis, and other unidentified causes.

Over the last few decades, assessing quality of life (QoL) of individuals with diseases has become common clinical practice,^{6,7} as a consequence of increased survival of patients with chronic diseases.⁸ The term health-related quality of life (HRQoL) reflects the impact of the disease upon a person's quality of life. It is a subjective, multidimensional concept addressing various aspects of the individuals' life such as age, gender, socioeconomic status, and type of illness, and treatment,⁹ that should be considered during patient evaluation.¹⁰

CLD has a negative impact on HRQoL since patients often present asthenia, indisposition, abdominal, muscle, and/or joint pain or discomfort, lack of appetite, insomnia, and complications related to liver cirrhosis, such as ascites, variceal bleeding in the stomach and esophagus, and hepatic encephalopathy. Moreover, CLD is linked to job loss, impaired functioning, mood swings, anxiety, low self-esteem, depression, and other emotional problems that severely affect QoL and well-being.¹¹⁻¹⁵

Globally, studies on HRQoL of patients with CLD have used generic and specific instruments.^{16,17} Recently, a Japanese version of the Chronic Liver Disease Questionnaire (CLDQ) to assess HRQoL was validated in patients with chronic viral hepatitis.¹⁸ To the best of our knowledge, this is the first study that assesses the HRQoL of Brazilian patients with CLD using a specific instrument that has been recently translated and validated for this population.¹⁹

Methods

Patients

Patients with CLD referred to the Outpatient Clinic of CLD at Hospital das Clínicas of the Federal University of Uberlândia, Minas Gerais State, Brazil in the period of 2011-2012 were recruited for the study. Patients of either gender had to be 18 years or more and have a diagnosis of CLD by a hepatologist.

The diagnosis of chronic hepatitis B virus (HBV) infection was based on the presence of hepatitis B surface antigen for more than six months and elevated serum alanine aminotransferase levels with or without HBV DNA, detected by real-time polymerase chain reactions (PCR).²⁰

Chronic hepatitis C virus (HCV) infection was diagnosed based on the presence of hepatitis C antibodies for more than six months assessed by ELISA III and HCV RNA by qualitative polymerase chain reaction and elevated serum alanine aminotransferase levels.²¹

Primary biliary cirrhosis was diagnosed based on positive anti-mitochondrial antibodies (AMA) and elevated liver enzymes with or without liver biopsy.²² Alcohol was deemed the cause of chronic liver disease if daily alcohol consumption was greater than 40 g for at least 10 years with elevated γ -glutamyl transferase when controlling for other liver diseases.²³

Autoimmune hepatitis diagnosis was based on simplified diagnostic criteria for routine clinical practice including age, sex, autoantibodies [smooth muscle actin (SMA), anti-nuclear

antibody (ANA), AMA, liver-kidney microsomal antibodies (LKM), soluble liver/liver-pancreas antibodies (SLA/LP)], γ -globulins, immunoglobulin A, immunoglobulin G (IgG), immunoglobulin M (IgM), absence of viral hepatitis, and liver histology.²⁴

Diagnosis of nonalcoholic fatty liver disease (NAFLD) was based in the evidence of hepatic steatosis, either by imaging or histology, controlling for other causes of secondary hepatic fat accumulation such as significant alcohol consumption, steatogenic medication, or hereditary disorders.²⁵ Cryptogenic chronic hepatitis was diagnosed if the patient presented with persistent inflammation of the liver, unexplained by conventional clinical, laboratory, and histological methods.²⁶

Liver cirrhosis diagnosis was based on clinical, biochemical, serologic, and radiographic parameters and ultrasonography.²⁷ Cirrhosis without a diagnosis of the etiology was termed "other forms of cirrhosis or unspecified cirrhosis".

Exclusion criteria were presence of malignancy, liver transplantation, co-infection with human immunodeficiency virus (HIV), psychiatric or emotional problems, cognitive or language difficulties that prevented the reliable application of the questionnaire, and a diagnosis of hepatic encephalopathy.⁶ The study was conducted in accordance with the Helsinki Declaration and study protocols were approved by local ethics committees. All patients provided informed consent before enrollment.

A pilot study to verify the applicability of these instruments was first conducted on 23 individuals with the same population characteristics. These patients were not included in the final sample.

Data collection

The investigators informed patients about the study aims. After obtaining informed consent, participants completed a socio-demographic questionnaire and the CLDQ.

The CLDQ has recently been translated and validated for the Brazilian population.¹⁸ This instrument was developed by Yonossi et al. in 1999 to assess QoL of patients with liver diseases.⁵ The CLDQ is the only validated instrument for the different etiologies and degrees of severity of liver disease. It yields both domains and total scores, demonstrating both multidimensional and overall perception of QoL, emphasizing the effects of liver disease symptoms. The Brazilian version comprises 29 questions encompassing six domains: Abdominal Symptoms (AS), Fatigue (FA), Systemic Symptoms (SS), Activity (AT), Emotional Function (EM), and Worry (WR). AS and AT domains have 3 items each; FA, SS, and WR have 5 items each; whereas EM comprises 8 items. Each item is rated on a 7-point Likert scale.²⁸ Higher score on the questionnaire is indicative of minimum symptoms and lower score indicates more pronounced symptoms. A CLDQ cut-off score was determined to evaluate HRQoL based on prior literature; mean CLDQ scores ≥ 5 was considered to represent high HRQoL and mean CLDQ scores < 5 implied low HRQoL.²⁹

The Model for End-Stage Liver Disease (MELD) index—a mathematical model that uses three laboratory tests (values of serum creatinine, serum total bilirubin, and international

normalized ratio; INR) to determine the severity of liver disease³⁰—was also calculated. The formula adopted by the United States (U.S.) Department of Health & Human Services was used: $\{0.957 \times \log_e [\text{creatinin (mg/dL)}] + 0.378 \times \log_e [\text{bilirubin (mg/dL)}] + 1.120 \times \log_e (\text{INR}) + 0.643\} * 10$.

For patients on dialysis more than twice a week, creatinine values were always registered at 4.0. All patients were categorized into groups, based on MELD scores: low (<15), moderate (16–25) and high (>25) risk of mortality. The MELD is used as a tool to guide liver organ allocation system for liver transplantation in the US, Europe, and Brazil.³⁰

Statistical analysis

Data were entered into Microsoft Excel, a spreadsheet program. Frequencies of variables were crosschecked for accuracy. Subsequently, this database was transferred to Epi Info™ 7.1.0.6, through which statistical analyses were performed. Categorical variables (e.g., gender, race/ethnicity, etiology of liver disease) are presented as frequencies and percentages, whereas continuous variables (MELD and CLDQ scores) are presented as means and standard deviations. To evaluate gender differences in average CLDQ scores, a Student's t-test was used, while analysis of variance (ANOVA) was used to compare differences in average CLDQ scores for different categories, level of education, occupation, and family income ($p < 0.05$ was considered significant). Pearson's correlation coefficient was used to verify the existence of correlation between the following variables: CLDQ scores, MELD scores, age, education, and family income.

Results

Sociodemographic and clinical characteristics

The socio-demographic characteristics of 133 patients with chronic liver disease of different etiologies are shown in Table 1. The majority of participants in this study were male (66.2%), Caucasian (70.7%), employed (42.9%), and had a family income of US\$329–US\$658.2 (43.6%). Over 27% had received up to four years of schooling. The participants' mean age was 50 ± 13.3 years. Regarding chronic liver etiology, 75 individuals were classified as chronic HCV patients (56.4%), 25 as HBV patients (18.8%), 15 with alcoholic liver cirrhosis (11.3%), 8 with autoimmune hepatitis (6%), 4 with NAFLD (3%), 1 with cryptogenic hepatitis (0.8%), and 5 had other causes of cirrhosis (3.8%).

CLDQ

Table 2 shows the minimum, maximum, mean, and standard deviation CLDQ scores. Higher mean CLDQ scores were found for emotional function (39.70 ± 12.98) while lower mean CLDQ scores were obtained for abdominal symptoms (16.00 ± 6.25). Fifty-two patients (39.1%) obtained low (<5) overall CLDQ scores. CLDQ was evaluated according to age, gender, family income and school level. Family income was correlated to CLDQ ($r = 0.187$, $p = 0.031$) (Table 3).

Table 1 – Socio-demographic characteristics of 133 chronic liver disease patients included in the study.

Variables	n	%
<i>Gender</i>		
Female	45	33.8
Male	88	66.2
<i>Race/ethnicity</i>		
No Caucasian	39	29.3
Caucasian	94	70.7
<i>Age (years)</i>		
≤40	29	21.8
41–50	33	24.8
51–60	40	30.1
>60	31	23.3
<i>Occupation</i>		
Retired	37	27.8
Unemployed	20	15.0
Housewife	10	7.5
Employee	57	42.9
Medical license	5	3.8
Prisoner	4	3.0
<i>Family income (dollars)</i>		
<US\$329	11	8.3
US\$329 to US\$658.2	58	43.6
US\$658.2 to US\$987.3	42	31.6
>US\$987.3	21	15.8
Did not answer	1	0.8
<i>Education level</i>		
Primary (4 years)	37	27.8
Secondary (5 and 8 years)	36	27.1
Incomplete high school (9 and 10 years)	21	15.8
High school (11 years)	28	21.1
Incomplete higher education (12 and 14 years)	8	6.0
Completed higher education (15 years)	3	2.3

MELD

Regarding MELD, 124 (93.2%) individuals were at low risk (≤15), seven (5.3%) were at moderate risk, and two (1.5%) were at high risk for mortality (>25). MELD indices were correlated to age ($r = 0.185$; $p = 0.033$; Table 3).

Discussion

Liver disease is a serious public health problem that affects patients' QoL. HRQoL measures are increasingly recognized as important tools for assessing disease outcomes and determining health interventions.¹⁷ The present study showed high mean CLDQ scores, indicating low HRQoL in the population studied.

The majority of participants were male, Caucasian, and infected by either hepatitis B or C viruses. This is consistent with other studies using similar methods.^{31,32} We selected the CLDQ in order to measure the HRQoL of patients with liver disease, regardless of etiology and severity.

Mean emotional functional CLDQ scores were high. The awareness of potentially life-threatening diseases may have adverse emotional effects on participants, regardless of biological consequences of the disease, as suggested by a prior

Table 2 – Chronic Liver Disease Questionnaire (CLDQ) score in domains.

Variable	Minimum score	Maximum score	Mean score	SD score
CLDQ domains				
Abdominal symptoms	3	36	16.00	6.25
Fatigue	5	35	23.35	9.32
Systemic symptoms	7	35	27.29	6.76
Activity	3	21	16.45	5.19
Emotion function	10	56	39.70	12.98
Worry	5	35	25.69	9.99
Total CLDQ	8.16	33.83	24.75	6.68

Table 3 – Univariate regression analysis of potential predictors of Chronic Liver Disease Questionnaire (CLDQ) and Model End-Stage Liver Disease (MELD) scores, Brazil, 2012.

Variables	Chronic Liver Disease Questionnaire (CLDQ)		Model End-Stage Liver Disease (MELD)	
	Pearson correlation coefficient (r)	p-Value	Pearson correlation coefficient (r)	p-Value
Meld	–0.051	0.562	NA	NA
Age	–0.031	0.727	0.185	0.033*
Education level	–0.061	0.486	–0.083	0.342
Family income	0.187	0.031*	–0.096	0.271

NA, not applicable.
* $p < 0.05$.

study.¹⁰ Previous research has also shown that depressive disorders are related to poor HRQoL in patients with CLD.¹³

The present study found a positive correlation between CLDQ scores and family income, implying that those with high family incomes had higher HRQoL, as demonstrated by Hsu et al. (2012).³³

On the other hand, CLDQ values were not related to age, gender, and level of education. Previous studies have shown that gender and education level were not related to the HRQoL of patients with liver disease.^{31,34,35} However, CLDQ scores decreased with advancing age; thus, HRQoL also decreased with age.^{36,37}

The MELD index was also used in the present study since it is the main criteria for allocation in liver transplantation waiting list. Most individuals had low MELD indices (scores <15) and were therefore considered to be at low risk of mortality. No correlation was observed between MELD and CLDQ scores. Ray et al. (2010) using CLDQ verified a weak correlation with MELD and concluded that MELD scores poorly predicted QoL, as evidenced in the present study.³⁸ However, a positive correlation was found for MELD scores and age, indicating that as age increases, MELD scores also increase, along with the risk of mortality due to liver disease. Luca et al. (2007) have suggested the inclusion of age into the original MELD formula in order to improve the predictive survival accuracy of patients with cirrhosis.³⁹

Globally, CLD substantially contributes to mortality and morbidity.^{5,6} Thus, understanding patients' HRQoL and the extent of debilitation is extremely important. A limited number of studies have been conducted to evaluate HRQoL in patients with liver disease in Brazil, most of which used generic instruments; even so, HCV infection was found to have a substantial impact on patients' HRQoL.^{13,40–42}

Health, as a social right of all citizens, requires direct and positive state intervention by providing services for diagnosis, treatment, and medical monitoring of diseases including CLD to improve their HRQoL.

This study has some limitations: the cross sectional nature of the study does not allow conclusions about causality; the inclusion of outpatients from one single center; and the necessity of a longitudinal study to determine the true impact on HRQoL in a large population based study.

In conclusion, this study found high mean CLDQ scores among a significant number of CLD patients particularly among those with low family income implying low HRQoL. This suggests that early identification of at-risk individuals with low income could help develop and assess relevant health programs intended to improve patients' HRQoL. In addition, MELD scores did not significantly predict QoL.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

The authors would like to thank the Coordination of the Improvement of Higher Education Personnel (CAPES), the Fundação de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), the Brazilian National Council of Technological and Scientific Development (CNPq) for financial support, and Samantha Mucci for providing permission to use the CLDQ questionnaire.

REFERENCES

1. Strong K, Mathers C, Leeder S, Beaglehole R. Preventing chronic diseases: how many lives can we save. *Lancet*. 2005;366:1578–82.
2. World Health Organization. Viral hepatitis: report by the Secretariat, March 2010. Geneva: World Health Organization; 2010.
3. Montuclard C, Hamza S, Rollot F, et al. Causes of death in people with chronic HBV infection: a population-based cohort study. *J Hepatol*. 2015;62:1265–71.
4. Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. *BMC Public Health*. 2009;9:34.
5. Center for Disease Control and Prevention. World Hepatitis Day, July 28; 2011. Available from URL: <http://www.cdc.gov/Features/dsHepatitisAwareness/> [cited 22.11.11].
6. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. *Gut*. 1999;45:295–300.
7. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. *Hepatology*. 2007;45:806–16.
8. Murdaugh C. Health-related quality of life as an outcome in organizational research. *Med Care*. 1997;35:NS41–8.
9. Glise H, Wiklund I. Health-related quality of life and gastrointestinal disease. *Gastroenterol Hepatol*. 2002;17:S72–84.
10. Amodio P, Salari L, Montagnese S, et al. Hepatitis C virus infection and health-related quality of life. *World J Gastroenterol*. 2012;18:2295–9.
11. Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. *Am J Gastroenterol*. 2001;96:2199–205.
12. Zhuang G, Zhang M, Liu Y, et al. Significant impairment of health-related quality of life in mainland Chinese patients with chronic hepatitis B: a cross-sectional survey with pair-matched healthy controls. *Health Qual Life Outcomes*. 2014;12:101.
13. Fábregas BC, de Ávila RE, Faria MN, Moura AS, Carmo RA, Teixeira AL. Health related quality of life among patients with chronic hepatitis C: a cross-sectional study of sociodemographic, psychopathological and psychiatric determinants. *Braz J Infect Dis*. 2013;17:633–9.
14. Nayak NC, Jain D, Vasdev N, Gulwani H, Saigal S, Soin A. Etiologic types of end-stage chronic liver disease in adults: analysis of prevalence and their temporal changes from a study on native liver explants. *Eur J Gastroenterol Hepatol*. 2012;10:1199–208.
15. Gutteling JJ, Duivenvoorden HJ, Busschbach JJ, de Man RA, Darlington AS. Psychological determinants of health-related quality of life in patients with chronic liver disease. *Psychosomatics*. 2010;51:157–65.
16. Kondo Y, Yoshida H, Tateishi R, Shiina S, Mine N, Yamashiki N. Health-related quality of life of chronic liver disease patients with and without hepatocellular carcinoma. *J Gastroenterol Hepatol*. 2007;22:197–203.
17. Matsushita H, Ikeda F, Iwasaki Y, et al. Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C. *J Gastroenterol Hepatol*. 2014;29:337–43.
18. Tanaka A, Kikuchi K, Miura R, et al. Validation of the Japanese version of the Chronic Liver Disease Questionnaire for the assessment of health-related quality of life in patients with chronic viral hepatitis. *Hepatol Res*. 2015 [Epub ahead of print].
19. Mucci S, Citero VA, Gonzalez M, et al. Validation of the Brazilian version of Chronic Liver Disease Questionnaire. *Qual Life Res*. 2013;22:167–72.
20. Chevaliez S, Bouvier-Alias M, Laperche S, Pawlotsky JM. Performance of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. *J Clin Microbiol*. 2008;46:1716–23.
21. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology*. 2009;49:1335–74.
22. European Association for the Study of the Liver. EASL clinical practice guideline: management of cholestatic liver disease. *J Hepatol*. 2009;51:237–67.
23. O'Shea RS, Dadarathy S, McCullough AJ, Practice Committee of the American College of Gastroenterology. Alcoholic liver disease. *Hepatology*. 2010;51:307–28.
24. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. *Hepatology*. 2008;48:169–76.
25. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology*. 2012;55:2005–23.
26. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. *Gastroenterology*. 1993;104:1755–61.
27. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. *J Hepatol*. 2006;44:217–31.
28. Likert R. A technique for the measurement of attitudes. *Archiv Psychol*. 1932;22:55.
29. Parkash O, Iqbal R, Jafri F, Azam I, Jafri W. Frequency of poor quality of life and predictors of health related quality of life in cirrhosis at a tertiary care hospital Pakistan. *BMC Res Notes*. 2012;5:446.
30. Habib S, Berk B, Chang C-CH, et al. MELD and prediction of post-liver transplantation survival. *Liver Transpl*. 2006;12:440–7.
31. Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. *Am Gastroenterol*. 2003;98:630–8.
32. Kim SJ, Han KT, Lee SY, Park EC. Quality of life correlation with socioeconomic status in Korean hepatitis-B patients: a cross sectional study. *Health Qual Life Outcomes*. 2015;13:55.
33. Hsu PC, Federico CA, Krajden M, et al. Health utilities and psychometric quality of life in patients with early and late stage hepatitis C virus infection. *J Gastroenterol Hepatol*. 2012;27:149–57.
34. Arguedas MR, DeLawrence TG, McGuire BM. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. *Dig Dis Sci*. 2003;48:1622–6.
35. Hauser W, Holtmann G, Grandt D. Determinants of health-related quality of life in patients with chronic liver diseases. *Clin Gastroenterol Hepatol*. 2004;2:157–63.
36. Sumskiene J, Sumskas L, Petrauskas D, Kupcinskas L. Disease-specific health-related quality of life and its determinants in liver cirrhosis patients in Lithuania. *World J Gastroenterol*. 2006;12:7792–7.
37. Gao R, Gao F, Li G, Hao JY. Health-related quality of life in Chinese patients with chronic liver disease. *Health Qual Life Outcomes*. 2013;11:131.
38. Ray I, Dutta D, Basu P, De BK. Quality of life assessment of patients with chronic liver disease in eastern India using a

- Bengali translation Chronic Liver Disease Questionnaire. *Indian J Gastroenterol.* 2010;29:187-95.
39. Luca A, Angermayr B, Bertolini G, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. *Liver Transpl.* 2007;13:1174-80.
 40. Teixeira MC, Ribeiro Mde F, Gayotto LC, Chamone Dde A, Strauss E. Worse quality of life in volunteer blood donors with hepatitis C. *Transfusion (Paris).* 2006;46:278-83.
 41. El Khoury AC, Vietri J, Prajapati G. Health-related quality of life in patients with hepatitis C virus infection in Brazil. *Rev Panam Salud Publica.* 2014;35:200-6.
 42. Quarantini LC, Miranda-Scippa Â, Batista-Neves S, et al. The effect of early virological response in health-related quality of life in HCV-infected patients. *J Med Virol.* 2008;80:419-23.